Document is current
Any future updates will be listed below
-
Authors
van Amstel, Rombout B. E.
Rademaker, Emma
Kennedy, Jason N.
Bos, Lieuwe D. J.
Peters-Sengers, Hessel
Butler, Joe M.
Bruse, Niklas
Dongelmans, Dave A.
Kox, Matthijs
Vlaar, Alexander P. J.
van der Poll, Tom
Cremer, Olaf L.
Seymour, Christopher W.
van Vught, Lonneke A.
-
Funding
Funding for this research was provided by:
Center for Translational Molecular Medicine (04I-201)
Center for Translational Molecular Medicine (04I-201)
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 6 January 2025
First Online: 4 February 2025
Declarations
:
: For the MARS cohorts, patients were included via an opt-out consent method approved by the institutional review boards of both participating hospitals ((Academic Medical Center in Amsterdam and University Medical Center in Utrecht) (IRB No. 10-056C). For MIMIC-IV, the institutional reviews board at the Beth Israel Deaconess Medical Center granted a waiver of informed consent and approved the data sharing initiative.
: Not applicable.
: Hessel Peter-Sengers reports funding from the Dutch Kidney Foundation (postdoc grant 19OK009). Olaf L Cremer reports funding from ZonMw, Health Holland, and Fund SGS; research support from Abionic SA, Prolira BV, and Presymptom Health Ltd; and consulting fees from ICRC. Lieuwe DJ Bos reports support from the Dutch Lung Foundation (Young Investigator Grant and Dirkje Postma Award), the Dutch Lung Foundation and Health Holland (Grant Public–Private Partnership), the IMI COVID19 initiative, Amsterdam UMC, ZonMW (COVID-19 Urgency Grant and VIDI Grant), the ERS Gold Metal for ARDS and unrestricted research grants from Santhera and Volition; consulting fees for Scailyte, Sobi, Exvastat, Santhera, Pfizer, Astra Zeneca, and Janssen paid to the institution. Alexander PJ Vlaar reports support by a Landsteiner Foundation for Blood Research (LSBR) fellowship grant, number 1931F. from the Landsteiner Foundation for Blood Transfusion Research, Haarlem – The Netherlands and by a personal grant of NWO (VIDI Grant number 09150172010047); and consulting fees from Edwards Lifesciences, CSL Behringe, InflaRx paid to the institution; and grants from Edwards Lifesciences, CSL Behringe, Terumo and Werfen. Jason N Kennedy and Christopher W Seymour were supported by the National Institutes of Health grant R35GM119519. Lonneke A van Vught was supported by the Netherlands Organisation for Health Research and Development ZonMW (Nederlandse Organisatie voor Wetenschappelijk Onderzoek NWO) VENI grant 09150161910033 and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Research Grant.
